Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
-5.45 (-3.87%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
51
52
Next >
Eli Lilly Skids, Weighing On Novo Nordisk, On A Key New Finding For Obesity Drugs
December 11, 2023
Researchers examined what happened after patients stopped taking Zepbound.
Via
Investor's Business Daily
Are These Biotechs Ready To Launch?
December 09, 2023
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...
Via
Talk Markets
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
December 08, 2023
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs.
Via
Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
December 08, 2023
Via
Benzinga
Why Viking Therapeutics Was Crushing It This Week
December 08, 2023
Nowadays, it's good to be a developer of next-generation weight loss drugs.
Via
The Motley Fool
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
December 08, 2023
These drugs address a rapidly growing market.
Via
The Motley Fool
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
December 02, 2023
This company famously helps manage a prevalent chronic illness.
Via
The Motley Fool
Will NOVO-NORDISK A/S-SPONS ADR breakout?
November 30, 2023
The technical analysis for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is highly positive, with a rating of 10 out of 10, suggesting a potential breakout.
Via
Chartmill
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
December 07, 2023
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.
Via
Investor's Business Daily
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer
Via
Benzinga
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
December 06, 2023
A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S's (NYSE: NVO) obesity treatment drug Wegovy in 2021 or 2022...
Via
Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
Via
Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
December 04, 2023
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Via
Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
December 04, 2023
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.
Via
Investor's Business Daily
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
December 04, 2023
Roche Holding AG (OTC: RHHBY) has agreed to
Via
Benzinga
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
December 04, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could...
Via
The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
December 03, 2023
No analysis paralysis is required with these great stocks.
Via
The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
December 02, 2023
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate...
Via
Talk Markets
An Important History Lesson for Gene-Editing Investors
December 02, 2023
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
Via
The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
December 02, 2023
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.
Via
The Motley Fool
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
December 01, 2023
Denmark's Health Minister, Sophie Lohde, has signaled the government's willingness to expand coverage for Novo Nordisk A/S's (NYSE: NVO) weight-loss drug Wegovy if the company shares some of the...
Via
Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...
Via
Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
December 01, 2023
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO).
Via
Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
December 01, 2023
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell.
Via
Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
December 01, 2023
Software earnings were strong, while the Fed is shifting toward rate cuts.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
December 01, 2023
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug.
Via
Talk Markets
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
December 01, 2023
Novo Nordisk stock has been a red-hot buy this year -- can it continue that trend through this decade?
Via
The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
November 30, 2023
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
November 30, 2023
Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.
Via
The Motley Fool
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
November 29, 2023
Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's (NYSE: NVO)
Via
Benzinga
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.